Trial Court Rules In Favor of Novel Labs. Invalidating Three Patents and Federal Circuit Summarily Affirms

Represented Novel Laboratories, Inc., a pharmaceutical company seeking to market a generic version of Intermezzo®. Intermezzo® is a sublingual formulation of zolpidem indicated for middle-of-the-night insomnia. Following a 10-day bench trial, Chief Judge Linares found in favor of our client, ruling that the asserted claims of all three patents-in-suit were invalid as obvious. The Federal Circuit confirmed the invalidity findings in a summary affirmance. LMG Life Sciences named this case one of the Hatch-Waxman Impact Cases of the Year in 2016. Purdue Pharm. v. Actavis Elizabeth LLC, 15-1659 (Fed. Cir.); Purdue Pharm. Products LP v. Actavis Elizabeth LLC, 12-5311 (D.N.J.).